Kulyova S A, Karitsky A P
Vestn Ross Akad Med Nauk. 2014(11-12):67-71.
Today approximately 70% of patients with Hodgkin lymphoma can be cured with the combined-modality therapy. Tumor burden, the importance of which was demonstrated 15 years ago for the first time, is a powerful prognostic factor. Data of literature of representations on predictive value of Hodgkin's lymphoma tumor burden are shown in the article. The difficult immunological relations between tumor cells and reactive ones lead to development of the main symptoms. Nevertheless, the collective sign of tumor burden shows the greatest influence on survival and on probability of resistance, which relative risk can be predicted on this variable and treatment program. Patients with bulky disease need escalated therapy with high-dose chemotherapy. Integration into predictive models of the variable will change an expected contribution of clinical and laboratory parameters in the regression analyses constructed on patients with Hodgkin's lymphoma. Today the role of diagnostic functional methods, in particular a positron emission tomography, for metabolic active measurement is conducted which allows excluding a reactive component.
如今，约70%的霍奇金淋巴瘤患者可通过综合治疗治愈。肿瘤负荷是一个强大的预后因素，其重要性在15年前首次得到证实。本文展示了关于霍奇金淋巴瘤肿瘤负荷预测价值的文献数据。肿瘤细胞与反应性细胞之间复杂的免疫关系导致了主要症状的出现。然而，肿瘤负荷的总体迹象对生存和耐药概率的影响最大，可基于此变量和治疗方案预测相对风险。有大块病灶的患者需要强化大剂量化疗。将该变量纳入预测模型将改变霍奇金淋巴瘤患者回归分析中临床和实验室参数的预期贡献。如今，正在开展诊断性功能方法的作用，尤其是正电子发射断层扫描用于代谢活性测量，这有助于排除反应性成分。
